More than 50% of NSCLC patients that are EGFR mutation-positive and who have experienced disease progression following EGFR-TKI treatment, have developed a T790 M resistance mutation, for which there has been few treatment options [65, 102]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.